Iron metabolism in patients with Graves' hyperthyroidism

被引:14
|
作者
Fischli, Stefan [1 ]
von Wyl, Viktor [2 ]
Trummler, Michael [3 ]
Konrad, Daniel [4 ,5 ]
Wueest, Stephan [4 ,5 ]
Ruefer, Axel [6 ]
Heering, Kerstin [1 ]
Streuli, Regina [1 ]
Steuer, Christian [7 ]
Bernasconi, Luca [7 ]
Recher, Mike [8 ,9 ,10 ]
Henzen, Christoph [1 ]
机构
[1] Luzerner Kantonsspital, Div Endocrinol & Diabet, Luzern, Switzerland
[2] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland
[3] Luzerner Kantonsspital, Dept Clin Chem, Luzern, Switzerland
[4] Univ Childrens Hosp, Div Pediat Endocrinol & Diabetol, Zurich, Switzerland
[5] Univ Childrens Hosp, Childrens Res Ctr, Zurich, Switzerland
[6] LuzernerKantonsspital, Div Hematol, Luzern, Switzerland
[7] Kantonsspital Aarau, Inst Lab Med, Aarau, Switzerland
[8] Univ Hosp Basel, Immunodeficiency Clin, Med Outpatient Clin, Basel, Switzerland
[9] Univ Hosp Basel, Dept Biomed, Basel, Switzerland
[10] Univ Basel, Basel, Switzerland
关键词
ferritin; Graves' hyperthyroidism; hepcidin; iron metabolism; SERUM FERRITIN LEVELS; TRANSCRIPTIONAL REGULATION; RESPONSIVE ELEMENT; HORMONE HEPCIDIN; MESSENGER-RNA; DISEASE; ERYTHROPOIESIS; THYROTROPIN; DISORDERS; REMISSION;
D O I
10.1111/cen.13450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Graves' hyperthyroidism (GH) interferes with iron metabolism and elevates ferritin. The precise mechanisms remain unclear. The influence of thyroid hormones on the synthesis/regulation of hepcidin, an important regulator of iron metabolism, remains uncharacterized. Design: Prospective observational study. Patients:We included patients (n=31) with new-onset and untreated GH. Measurements: Laboratory parameters indicative of iron metabolism (ferritin, transferrin, hepcidin), inflammatory markers/cytokines and smoking status were assessed at the diagnosis of GH (T0) and at euthyroidism (T1) in the same patients using multivariable analyses. Hepcidin was measured by mass spectrometry (hepcidin(MS)) and ELISA (hepcidin(EL)). The impact of T3 on hepatic hepcidin expression was studied in a cell culture model using HepG2 cells. Results: Median ferritin levels were significantly lower and transferrin significantly higher at T1 than at T0. Hepcidin(MS) levels were lower in males and females at T1 (statistically significant in males only). No statistically significant difference in hepcidin(EL) was detected between T0 and T1. Plasma levels of inflammatory markers (high-sensitive CRP, procalcitonin) and cytokines (interleukin 6, interleukin 1 ss, tumour necrosis factor ) were not different between T0 and T1. Smokers tended to have lower fT3 and fT4 at T0 than nonsmoking GH patients. T3 significantly induced hepcidin mRNA expression in HepG2 cells. Conclusions: Iron metabolism in patients with GH undergoes dynamic changes in patients with GH that resemble an acute-phase reaction. Inflammatory parameters and cytokines were unaffected by thyroid status. Gender and smoking status had an impact on ferritin, hepcidin and thyroid hormones.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 50 条
  • [21] Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye
    Sabini, Elena
    Ionni, Ilaria
    Rocchi, Roberto
    Vitti, Paolo
    Marcocci, Claudio
    Marino, Michele
    EUROPEAN THYROID JOURNAL, 2018, 7 (01) : 51 - 54
  • [22] Decreased number of circulating endothelial progenitor cells in patients with Graves' hyperthyroidism
    De Ciuceis, C.
    Pilu, A.
    Cappelli, C.
    Porteri, E.
    Zani, F.
    Santoro, A.
    Gandossi, E.
    Boari, G. E. M.
    Rizzardi, N.
    Castellano, M.
    Rizzoni, D.
    Rosei, E. Agabiti
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (05) : 335 - 339
  • [23] GRAVES HYPERTHYROIDISM AND PREGNANCY: A CLINICAL UPDATE
    Patil-Sisodia, Komal
    Mestman, Jorge H.
    ENDOCRINE PRACTICE, 2010, 16 (01) : 118 - 129
  • [24] Biventricular Takotsubo Cardiomyopathy in Graves Hyperthyroidism
    Perkins, Matthew J.
    Schachter, David T.
    JOURNAL OF INVASIVE CARDIOLOGY, 2014, 26 (03) : E35 - E36
  • [25] New Therapeutic Horizons for Graves' Hyperthyroidism
    Lane, Laura C.
    Cheetham, Tim D.
    Perros, Petros
    Pearce, Simon H. S.
    ENDOCRINE REVIEWS, 2020, 41 (06) : 873 - 884
  • [26] Tremelimumab-Induced Graves Hyperthyroidism
    Gan, Earn H.
    Mitchell, Anna L.
    Plummer, Ruth
    Pearce, Simon
    Perros, Petros
    EUROPEAN THYROID JOURNAL, 2017, 6 (03) : 167 - 170
  • [27] An update on the medical treatment of Graves' hyperthyroidism
    Marino, Michele
    Latrofa, Francesco
    Menconi, Francesca
    Chiovato, Luca
    Vitti, Paolo
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (11): : 1041 - 1048
  • [28] Clinical manifestations and early effectiveness of methimazole in patients with graves' hyperthyroidism-related severe hepatic dysfunction
    Li, Chen
    Wang, Kai-li
    Hu, Jin-hua
    Su, Hai-bin
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1514 - 1522
  • [29] Toward Ultimate Care for Graves' Hyperthyroidism
    Azizi, Fereidoun
    Abdi, Hengameh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 18 (01)
  • [30] Dysregulated Iron Metabolism in Patients on Hemodialysis
    Nakanishi, Takeshi
    Hasuike, Yukiko
    Otaki, Yoshinaga
    Nanami, Masayoshi
    Kuragano, Takahiro
    CHRONIC KIDNEY DISEASES - RECENT ADVANCES IN CLINICAL AND BASIC RESEARCH, 2015, 185 : 22 - 31